Range of Varicella Zoster Co-Infections with COVID-19, Singapore

Abstract

There have been recent descriptions of the novel coronavirus disease 2019 (COVID-19) presenting as ‘varicella-like exanthem’. We report three cases of patients with Varicella-Zoster Virus (VZV) and COVID-19 co-infections, presenting in three varied ways. These cases highlight the need for heightened alertness to how such co-infections can present, to pick up overlapping ‘dual pathologies’ during this current pandemic given that infection control measures including airborne precautions are crucial for both COVID-19 and VZV.

Introduction

There have been recent descriptions of the novel coronavirus disease (COVID-19) presenting with ‘varicella-like exanthema’ [1,2]. Initial queries had been if such papulovesicular eruptions could be herpes simplex virus or varicella zoster virus (VZV) co-manifesting with COVID-19 [3,4]; though dual simultaneous viral infections would be unusual. Herein we describe 3 patients diagnosed with VZV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infections with varying presentations.

Case report

Patient 1, 39-year-old male presented with fever and generalized pruritic vesicular rash of 3 days, in a head-to-centripetal distribution (Fig. 1A, 1B). He also tested for nasopharyngeal SARS-CoV-2 by polymerase chain reaction (PCR) (cobas SARS-CoV-2 Test; Roche Molecular Systems, Branchburg, NJ, USA) due to known exposure (Ct value- E gene: 35.76). On day 4 he deteriorated requiring supplemental oxygen. Thoracic imaging showed pulmonary nodules consistent with varicella pneumonia (Fig. 1C, 1D). The vesicular fluid tested positive for varicella DNA by PCR (VZV ELITe MGB^® Kit; ELITechGroup, Puteaux, France); his sera was VZV IgM and IgG positive.

Figure 1. Clinical Features of Patients with Varicella and COVID-19 Co-infections.

(A) Clinical Photograph, Patient 1, Vesicular rash on face. (B) Clinical Photograph, Patient 1, Vesicular rash on trunk. (C) Computed Tomography Thorax, Patient 1. (D) Computed Tomography Thorax, Patient 1. (E) Clinical Photograph, Patient 3, Papulo-vesicular rash on face. (F) Clinical Photograph, Patient 3, Papulo-vesicular rash on trunk.

Patient 2, 24-year-old male presented with 2 days of fever, cough and pruritic vesicular rash, again from a head-to-centripetal distribution. He had potential COVID-19 exposure distinct from Patient 1 and was SARS-CoV-2 PCR positive (Ct value- E gene: 35.76). The vesicular fluid PCR detected varicella DNA but was negative for SARS-CoV-2.

Patient 3, 32-year-old male had fever and cough for 2 days. He was positive for SARS-CoV-2 via nasopharynx PCR (Ct value- E gene: 35.15), but developed generalized papulo-vesicular rash one week later (Fig. 1E, 1F). The patient declined vesicular and blood sampling. Primary varicella was diagnosed clinically based on classical morphological evolution and centripetal distribution.

All the patients had no common epidemiological contact. They were unacquainted; had resided and worked at different locations. All were given acyclovir with improvement. These cases beget the question whether SARS-CoV-2 infection attenuates host immunity, modulates host antiviral lymphocyte function and potentiates susceptibility to opportunistic pathogens [5]. Conversely hyperinflammatory states, recognized in SARS-CoV-2 infection [6], can be a trigger to uncover latent susceptibilities to Mycobacteria or Varicella [7,8,9]. However, circulating interleukin-6 incidentally measured for Patient 1 was not elevated at 8.8 pg/mL (normal 1 - 10 pg/mL).

The study was approved by the Institutional Review Board of the National Healthcare Group, Singapore (Approval number: DSRB 2021/00513). Written consent was obtained in each case for use of medical information in this report (Patient 2 declined photo documentation).

Discussion

We demonstrate the range of clinical presentations in COVID-19-VZV co-infections. Patient 1 had predominant VZV manifestation. Patient 2 had classical VZV skin lesions with upper respiratory symptom from onset. Dermatological presentation of Patient 3 was delayed, one week after COVID-19 diagnosis; similar to patients described by Marzano et al. [1].

Densely-populated locations promote co-transmission of highly infectious pathogens like SARS-CoV-2 and VZV. This can account for occurrence of co-infections epidemiologically short of invoking pathogen-evoked immunomodulation posing public health risks in living spaces like dormitories and community isolation facilities. These cases highlight the need for heightened alertness to pick up overlapping ‘dual pathologies’ during this current pandemic.